Impact Of Early Endoscopic Remission After Advanced Therapy On Long-Term Complications In Ulcerative Colitis: Findings From TARGET-IBD.

Challenge

Achieving early endoscopic remission is a key treat-to-target goal in UC, but real-world evidence linking early endoscopic remission after advanced therapy initiation to long-term reductions in complications—hospitalization, colectomy, disease progression—had not been established in a large prospective US cohort.

Solution

The TARGET-IBD registry was used to compare long-term complication rates between UC patients who achieved early endoscopic remission after advanced therapy and those who did not, using time-to-event analyses to quantify the downstream benefits of achieving the treat-to-target endpoint.

Impact

Demonstrating that early endoscopic remission after advanced therapy is associated with significantly lower rates of long-term UC complications provides the clinical meaningfulness evidence for endoscopic remission as a treat-to-target endpoint, directly supporting Merck's regulatory and payer strategy for its UC portfolio.